SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
16251815
Source:
http://linkedlifedata.com/resource/pubmed/id/16251815
Search
Subject
(
54
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0011570
,
umls-concept:C0030705
,
umls-concept:C0033522
,
umls-concept:C0220847
,
umls-concept:C0338656
,
umls-concept:C0439230
pubmed:dateCreated
2005-10-27
pubmed:abstractText
This study assessed the rates and course of depressive symptomatology and neurocognitive deficits in hepatitis C virus (HCV) patients undergoing interferon treatment, and explored possible predictors of depression and neurocognitive deficits.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/8710219
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents
,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha
,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols
,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
,
http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin
,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
,
http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0269-9370
pubmed:author
pubmed-author:DieterichDouglas TDT
,
pubmed-author:GormanJack MJM
,
pubmed-author:ReichenbergAbrahamA
pubmed:issnType
Print
pubmed:volume
19 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S174-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16251815-Adult
,
pubmed-meshheading:16251815-Aged
,
pubmed-meshheading:16251815-Antiviral Agents
,
pubmed-meshheading:16251815-Cognition Disorders
,
pubmed-meshheading:16251815-Depressive Disorder
,
pubmed-meshheading:16251815-Drug Therapy, Combination
,
pubmed-meshheading:16251815-Female
,
pubmed-meshheading:16251815-Follow-Up Studies
,
pubmed-meshheading:16251815-Hepatitis C
,
pubmed-meshheading:16251815-Humans
,
pubmed-meshheading:16251815-Interferon-alpha
,
pubmed-meshheading:16251815-Male
,
pubmed-meshheading:16251815-Middle Aged
,
pubmed-meshheading:16251815-Polyethylene Glycols
,
pubmed-meshheading:16251815-Prospective Studies
,
pubmed-meshheading:16251815-Psychiatric Status Rating Scales
,
pubmed-meshheading:16251815-Recombinant Proteins
,
pubmed-meshheading:16251815-Ribavirin
pubmed:year
2005
pubmed:articleTitle
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.
pubmed:affiliation
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA. avi.reichenberg@mssm.edu
pubmed:publicationType
Journal Article
,
Clinical Trial